DMDD can inhibit hepatic stellate cell activation and TGF-β pathway overactivation by up-regulating the expression of tight junction protein, reducing endotoxemia, and reducing enteric harmful substances entering the liver through the portal vein, thus ultimately alleviating fibrosis (Figure 7). Here, TGFB1 is linked to serum lipopolysaccharide activity.